Drug intelligence / Profile preview

JS017

Development stage: Unknown
Lead developer: Junshi Biosciences
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

JS017 is an antibody-drug conjugate (ADC) targeting Claudin 18.2 (CLDN18.2), a protein frequently overexpressed in various gastrointestinal cancers, including gastric, esophageal, and pancreatic tumors. Developed by TopAlliance Biosciences (Junshi Biosciences), JS017 consists of a monoclonal antibody specific to CLDN18.2 conjugated to a cytotoxic payload. Upon binding to CLDN18.2 on the surface of tumor cells, the ADC is internalized, and the payload is released to induce cell death. It is currently being evaluated in Phase 1 clinical trials for the treatment of gastrointestinal malignancies.

Targets

TUBB (Tubulin (alpha and beta subunits))Claudin 18.2

Beyond the preview

Go deeper on JS017.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JS017.

Explore the full profile